Showing: 5 Results
Trial
Psychiatry

A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Active recruiting

The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

Contact: Oladele (Dickson) Owasoyo 217-545-7231
Trial
Neurology

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)

Active not recruiting

The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

Active recruiting

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois.  AD patients and their caregivers who are living in private homes will be recruited.  Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13  The patient and caregiver dyad is required.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Psychiatry

RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression

Active recruiting

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

Contact: Oladele (Dickson) Owasoyo 217-545-7231